Shenyang Sunshine Pharmaceutical Co. Ltd.

Ascentage Pharma (suzhou) Co., Ltd.

Ascentage Pharma Group Corp Limited

University of Michigan

Jiangsu Ascentage Biomed Development Inc.

Ascentage Pharma Co., Ltd.

Lingling Jiao

Yunlong Zhou

Yu Jing

Ming Guo

Jianyong Chen

Ping Min

Guangfeng Wang

Suixiong Cai

Shaomeng Wang

Chao-Yie Yang

Guozhi Tang

Liu Liu

Dajun Yang

Donna McEachern

Longchuan Bai

Chao Li

Hao Chen

Liugen Li

Wenliang Hu

Binghua Sheng

Leilei Zhao

Chengzhe Wu

Xu Qian

Provided are compounds represented by Formula (I-A) and the pharmaceutically acceptable salts and solvates thereof, wherein R, R, R, R, R, X, Y, Z, Z, W, and (aa) are as defined as set forth in the specification. Provided are also compounds of Formula (I-A) for use to treat a condition or disorder responsive to Mcl-1 inhibition such as cancer. 

Macrocyclic spiroethers as Mcl-1 inhibitors

The present disclosure provides compounds represented by Formula I: wherein R, A, A, A, A, E, E, E, L, Q, Z, and are as defined in the specification, and the pharmaceutically acceptable salts and solvates thereof. Compounds of Formula I are KRAS inhibitors and are thus useful to treat cancer and other diseases.

Spirocyclic tetrahydroquinazolines

A compound of the following formula (I) or a pharmaceutically acceptable salt thereof, wherein Rand Rare independently H; Ris selected from H, a C-Cstraight-chain, and a branched or cyclic alkyl; and R, R, R, R, and Rare each independently selected from C-Calkyl, halo C-Calkyl and the like. Also provided is a method for preparing the compound, pharmaceutical compositions including the compound or pharmaceutically acceptable salts thereof, and uses of the compound or pharmaceutically acceptable salt thereof in the preparation of a medicine for inhibiting HIF prolyl hydroxylase or a medicine for promoting the generation of endogenous EPO. 

Compound of 3-hydroxyl pyridine, preparation method thereof and pharmaceutical use thereof

A compound of 5-hydroxyl-1,7-naphthyridine substituted by aryloxy or heteroaryloxy, a preparation method thereof and a pharmaceutical use thereof are provided. In particular, the compound has the following Formula (I), wherein Rand Rare each independently H; Ris H or C-Calkyl; Ar is an aromatic ring or a heteroaromatic ring selected from a naphthalene ring, a pyridine ring, a thiophene ring, a furan ring and a substituted benzene ring. Pharmaceutically acceptable salts of the present compound, are provided, as well as uses of the compound or pharmaceutically acceptable salts thereof in the preparation of a medicine for inhibiting HIF prolyl hydroxylase or a medicine for promoting the generation of endogenous EPO. 

Compound of 5-hydroxyl-1,7-naphthyridine substituted by aryloxy or heteroaryloxy, preparation method thereof and pharmaceutical use thereof

Disclosed are a compound of the following formula (I) or a pharmaceutically acceptable salt thereof, a preparation method thereof, pharmaceutical compositions and uses thereof in the preparation of a medicine for inhibiting HIF prolyl hydroxylase or a medicine for promoting the generation of endogenous EPO, wherein in the formula (I), Rand Rare each independently hydrogen; Ris hydrogen or Calkyl; and Ar is an aromatic ring or an heteroaromatic ring selected from a naphthalene ring, a pyridine ring, a thiophene ring, a furan ring and a substituted benzene ring. 

Compound of 5-hydroxyl-1,7-naphthyridine substituted by aryl or heteroaryl, preparation method thereof and pharmaceutical use thereof

Disclosed herein are certain indoloquinolone compounds, methods of preparation thereof, pharmaceutical compositions thereof, and uses thereof, such as their uses as ALK inhibitors.

Indoloquinolone compounds as anaplastic lymphoma kinase (ALK) inhibitors

Growing community of inventors

Jiangsu, China

Lingling Jiao